Imugene Limited Revenue and Competitors
Estimated Revenue & Valuation
- Imugene Limited's estimated annual revenue is currently $14.3M per year.
- Imugene Limited's estimated revenue per employee is $155,000
Employee Data
- Imugene Limited has 92 Employees.
- Imugene Limited grew their employee count by 241% last year.
Imugene Limited's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & Managing Director | Reveal Email/Phone |
2 | Chief Business Officer | Reveal Email/Phone |
3 | VP - Clinical Operations | Reveal Email/Phone |
4 | VP CMC | Reveal Email/Phone |
5 | Director Clinical Operations | Reveal Email/Phone |
6 | Executive Director, Clinical Science | Reveal Email/Phone |
7 | Validation Program Manager | Reveal Email/Phone |
Imugene Limited Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $376.5M | 2429 | 9% | N/A | N/A |
#2 | $1.1M | 7 | -22% | N/A | N/A |
#3 | $7.5M | 61 | 20% | $106.1M | N/A |
#4 | $11.3M | 73 | N/A | N/A | N/A |
#5 | $18.6M | 120 | 33% | N/A | N/A |
#6 | $20.3M | 131 | 7% | N/A | N/A |
#7 | $1.7M | 11 | -72% | N/A | N/A |
#8 | $69.3M | 447 | 37% | N/A | N/A |
#9 | $28.7M | 185 | 5% | N/A | N/A |
#10 | $25M | 161 | 55% | N/A | N/A |
What Is Imugene Limited?
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. ASX: IMU
keywords:N/A
N/A
Total Funding
92
Number of Employees
$14.3M
Revenue (est)
241%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Sydney
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $26.7M | 92 | 10% | N/A |
#2 | $20.2M | 92 | 3% | N/A |
#3 | $15M | 92 | 10% | N/A |
#4 | $20.2M | 92 | 19% | N/A |
#5 | $13.8M | 92 | 19% | N/A |